Welcome to our dedicated page for Atricure news (Ticker: ATRC), a resource for investors and traders seeking the latest updates and insights on Atricure stock.
AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AtriCure, Inc. (NASDAQ: ATRC), known for its innovative therapies for atrial fibrillation (Afib) and related conditions, announced an upcoming investor education webcast in collaboration with Canaccord Genuity, focusing on Cryo Nerve Block Therapy. This event is scheduled for May 16, 2023, at 12:30 PM Eastern Time, featuring a Q&A session with management and a key opinion leader.
Additionally, AtriCure will present at the 2023 Bank of America Health Care Conference on May 10, 2023, at 11:00 AM Eastern Time. Both events aim to enhance investor understanding of AtriCure's cutting-edge technologies, including the Isolator® Synergy™ Ablation System, which is FDA-approved for persistent Afib treatment.
Interested participants can access live and archived webcasts through the Investors section of AtriCure's website.
AtriCure, Inc. (NASDAQ: ATRC), a leader in surgical treatments for atrial fibrillation (Afib), announced its first quarter 2023 financial results will be released on May 2, 2023. The company will host an audio webcast at 4:30 p.m. Eastern Time on the same day to discuss these results. Interested participants can register here. AtriCure focuses on innovative technologies for Afib treatment, with products like the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, addressing a condition affecting over 37 million people worldwide.